Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of 146 adults, with a median age of 50 years, previously receiving GO. SOS prophylaxis was used in 69 patients (heparin n = 57, ursodeoxycholic acid n = 8, defibrotide n = 4). Cumulative incidence (CI) of SOS was 8% (n = 11), with death in 3 patients. Median interval between last GO dose and HSCT was 130 days. Overall survival (OS) and SOS incidence did not differ for patients receiving GO ⩽ 3.5 months before HSCT and the others. CI of acute and chronic GVHD was 31% and 25%, respectively. Probability of OS and leukemia-free survival (LFS) at 5 years was 40% and 37%, respectively. Relapse incidence and non-relapse mortality were 42% and 21%, respectively. In multivariate analysis, active disease at HSCT was associated with relapse and worse LFS and OS (P o 0.03). Liver abnormalities before HSCT correlated with worse OS (P o 0.03). Use of low-dose GO prior to HSCT is associated with an acceptable SOS incidence. Prospective studies investigating the role and the utility of SOS prophylaxis are warranted.
INTRODUCTION
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD, referred as SOS thereafter) is a complication occurring most commonly in patients undergoing hematopoietic stem cell transplantation (HSCT). Its mean prevalence after HSCT in historical cohorts is nearly 14% (range 0-60%), with large variability related to well-known risk factors. 1 Its diagnosis is essentially clinical and investigator based still relying on the use of clinical criteria, including weight gain, ascites, tender hepatomegaly and jaundice. SOS usually develops by 30 days after HSCT, although it can occur later. 2 Gemtuzumab ozogamicin (GO) is a humanized monoclonal antibody targeting CD33+ AML blasts. It is conjugated to calicheamicin, an antitumor anthracycline antibiotic. 3 Significant concerns still exist about its safety, largely limiting its use in clinical practice. It has indeed been reported that liver toxicity (that is, hyperbilirubinemia and transaminases' elevation) especially SOS are increased, if it is used prior to HSCT. 4 GO monotherapy (two IV infusions of 9 mg/m 2 at 2 week interval) was first used for refractory or relapsed AML in patients aged 460 years, with a response rate of 26%. However, in that study the overall incidence of SOS was 5%, ranging from 0.9% in patients who received GO without being transplanted to 17% in patients undergoing HSCT. Subsequent results from a smaller cohort suggested that patients being transplanted with an interval ⩽ 3.5 months after GO administration (at a dose of either 6 or 9 mg/m 2 ) are at increased risk of SOS. 5 The SWOG-0106 trial tested the association of GO with induction chemotherapy regimens in younger patients, reporting an excess of induction mortality, a finding that led to GO being withdrawn from the US market. 6 Later on, encouraging results from other prospective trials with a similar scheme suggested its feasibility with an acceptable safety profile. 7, 8 Later on, in order to reduce GO toxicity, the French study ALFA 0701 9 proposed a fractionated schedule with low-dose GO of 3 mg/m 2 (given at days 1, 4 and 7), allowing outcome improvements in 140 AML patients. Interestingly, in that cohort, three SOS events (two of which were fatal) were described in patients receiving GO without undergoing subsequent HSCT, while no cases of SOS were reported in transplanted patients.
The primary end point of the current retrospective study was to assess the cumulative incidence (CI) of SOS in a population of patients undergoing HSCT after previous exposure to GO.
PATIENTS AND METHODS
This retrospective multicenter study, approved by the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT), included adults (418 years) diagnosed with AML and receiving HSCT from a matched or mismatched related or unrelated donor. Patients were treated with at least one dose of GO, either as a single agent or associated with chemotherapy, before HSCT. Patients receiving a myeloablative (MAC) or a reduced intensity conditioning (RIC) regimen were included. Included were patients transplanted in the period from 2002 to 2012.
Demographics, AML treatment and disease characteristic details, transplantation and post-transplantation data were extracted from the EBMT database (Med-A forms). Furthermore additional data were requested from investigators and collected (Med-C data) in each center. After giving their consent to participate if they had patients fulfilling inclusion criteria, transplant centers received a specifically prefilled clinical form where details concerning GO treatment and SOS had to be filled in. Seventeen centers contributed cases for the study.
Definitions
Cytogenetic abnormalities were classified as favorable, intermediate or high risk, as previously described. 10 The conditioning regimen was defined as RIC when fludarabine was associated with low-dose TBI (⩽6 Gy) or to a dose of oral busulfan o 8 mg/kg or a dose of IV busulfan o 6.4 mg/kg or other immunosuppressive or chemotherapeutic drugs, such as melphalan or cyclophosphamide and as MAC when it contained TBI or busulfan at greater doses. Neutrophil engraftment was defined as an ANC 40.5 × 10 9 /L for 3 consecutive days. Platelet engraftment was defined as an absolute platelet count 420 × 10 9 /L for 3 consecutive days. Acute and chronic GVHD were diagnosed and graded according to standard criteria. 11 Preexisting liver comorbidities were graded according to the HCT-specific comorbidity index, 12 while Karnofsky performance status was used to assess the patient functional status at HSCT.
The severity of adverse events was evaluated using the NCI common toxicity criteria v4.0. 13 Hepatic toxicity was defined by the presence of either transaminases or bilirubin elevation during GO treatment. As median time to platelet recovery reported in clinical trials after GO administration is 3-4 weeks, 14 we preferred to register occurrence of thrombocytopenia and its grade at 6 weeks after GO administration, in order to avoid underestimation of this event.
Time from GO to HSCT was defined as the number of days between the last dose of GO and day 0 of transplantation.
All cases meeting the definition of SOS as judged by the investigators were considered. Time to onset of SOS was considered typical when SOS occurred ⩽ 21 days (as reported in previous clinical criteria 15 ), atypical in all other cases. Each patient considered as having developed SOS by the investigator was then evaluated for the presence of either Seattle 15 or Baltimore clinical criteria. 16 Subsequently, each case of SOS was classified by the degree of diagnosis certainty according to the following definitions: (a) 'possible' when the diagnosis was not clear (that is, only one of the established criteria was met) and when the temporal sequence between exposure to GO and the onset of liver dysfunction was atypical, (b) 'probable' when the diagnosis of SOS did not meet all established criteria or when the temporal sequence and the onset of liver dysfunction was atypical, (c) 'confirmed' when the diagnosis fit established criteria with a characteristic temporal sequence.
Disease severity was classified as mild, moderate or severe according to the degree of hepatic dysfunction, the need for therapy and the outcome, as previously reported. 17 Surviving patients were censored at last follow-up, and death was considered an event. The duration of follow-up was the time to the last assessment for survivors. Non-relapse mortality (NRM) was defined as any death not related to relapse; overall survival (OS) was defined as the probability of being alive, regardless of disease status, at any time point. Leukemia-free survival (LFS) was defined as the probability of being alive and disease free at any time point; both death and relapse were considered events, and patients who were alive and leukemia-free were censored at last follow-up.
Statistical analysis
Median value and ranges were reported for continuous variables and percentages for categorical variables. Variables related to patients, disease and transplant were compared among patients developing SOS or not. Chi-square was used for categorical variables and Mann-Whitney for continuous variables.
The primary end point of the study was the assessment of the incidence of SOS after HSCT in patients previously treated with GO. Secondary end points were OS, relapse incidence (RI), LFS, NRM, acute and chronic GVHD rates. Probabilities of OS and LFS were calculated using the Kaplan-Meier estimates. 18 The log-rank test was then used for univariate comparisons. CI analysis was used for SOS, GVHD, engraftment and RI in a competing risk setting, with death being a competing event. Gray test was used for univariate comparisons 19 for the following variables: age at HSCT, gender, disease status, type of donor, stem cell source, type of conditioning regimen, busulfan-containing regimen, liver comorbidities, presence of hepatic abnormalities after GO treatment, CMV serostatus, Karnofsky performance status, GO dose, and use of anthracyclines.
All potential prognostic factors and those known to influence outcome were included in the multivariate analysis of survival and then included in the Cox proportional hazard model. Multivariate analysis was not performed for SOS, owing to the low number of patients developing the event.
All tests were two sided, with the type I error rate fixed at 0.05. Statistical analyses were performed with the SPSS 19 (SPSS Inc, Chicago, IL, USA), and R 3.0.1 (R Development Core Team, Vienna, Austria) software packages.
RESULTS
Patients, disease and transplant characteristics are summarized in Table 1 . One hundred and forty-six patients (75 men and 71 women) were included in the current study. Their median age at diagnosis was 50 years (range 19-70). Information on the treatment schedule of GO before HSCT was available for 137 patients: GO was mostly combined with chemotherapy (n = 127) and used as a single agent in the remaining cases (n = 10). Most patients (n = 79) received GO as induction treatment, while 51 and 16 were treated with this agent in the presence of relapsing or primary refractory disease, respectively. The median dose of GO was 3 mg/m 2 (range 3-9). Thirty-three patients received a fractionated schedule, with either 2 or 3 doses of GO for each cycle.
Thirty-six patients (out of 130 with available information) received SOS prophylaxis during GO treatment (ursodeoxycolic acid, n = 5; heparin, n = 31). Four patients were classified as having developed SOS after GO treatment, with two certain and two possible forms (overall incidence 3%). In one of the certain SOS, development of clinical signs despite heparin prophylaxis prompted the start of defibrotide.
At the time of HSCT, 97 patients were in CR (CR1, n = 54; CR2 or higher, n = 43) and 49 had an active disease (primary refractory, n = 16; first relapse, n = 22; second relapse, n = 8; progression, n = 3). Nineteen patients received a previous HSCT (11 allogeneic and 8 autologous). Hepatic comorbidity was reported in 15 patients (mild, n = 13; moderate/severe, n = 2). The conditioning regimen was myeloablative in 62 patients, RIC in the remaining 84.
A total of 94 patients developed hyperbilirubinemia after HSCT, mostly being grade 1 (n = 68), whereas 14 were grades 3-4.
During the HSCT period, SOS prophylaxis was given to 69 (47%) patients (heparin n = 57, ursodeoxycholic acid n = 8, defibrotide n = 4), with the remaining patients (53%) not receiving any prophylaxis.
SOS after HSCT
The details on each patient who developed SOS are summarized in Table 2 . The CI of SOS at day 150 was 8 ± 4% ( Figure 1 ). Eleven patients developed SOS after HSCT, with three confirmed and eight probable forms. Two out of the 11 patients received fractionated GO (patients 9 and 10 in Table 2 ). The median time from HSCT to SOS was 25 days (range 5-153). Eight out of the 11 patients received SOS prophylaxis (heparin, n = 5; ursodeoxycholic acid, n = 1; defibrotide, n = 2).
Of note, in two patients no treatment for SOS was given as investigators also considered the possibility of a hepatic GVHD. Four patients did not receive additional treatment owing to early death (hematological disease progression, n = 2; SOS, n = 2).
The SOS resolved in 4 patients after defibrotide (n = 2, with one already receiving defibrotide as prophylaxis), heparin+transjugular intrahepatic portosystemic shunt (n = 1) or symptomatic treatment (n = 1). Death owing to SOS occurred in one patient receiving symptomatic treatment and in other two patients who did not receive any treatment.
Globally, in terms of SOS severity, two mild, six moderate and three severe forms were reported.
According to the conditioning regimen, the CI of SOS was 11% (n = 7) and 5% (n = 4) in patients receiving a MAC and RIC regimen, respectively (P = 0.056).
A late-onset SOS, at 153 days after HSCT, was described in one high-risk patient (history of previous autologous HSCT, previous hepatic comorbidity and grade 3-4 liver toxicity during GO treatment). Of note, this patient received heparin prophylaxis during HSCT.
Owing to the low number of patients developing SOS, no univariate or multivariate risk factor analyses for SOS were performed.
Outcomes Details on the main outcomes together with univariate analysis results are reported in Table 3 .
Engraftment, GVHD, relapse and NRM The CI of day-60 neutrophil engraftment was 94 ± 3%, with a median of 15 days (range 6-62) after HSCT, while that of day-180 platelet engraftment was 89 ± 4% with a median of 15 days (range 4-196). Abbreviations: BM = bone marrow; CsA = ciclosporine A; DEF = defibrotide; F = female; GO = gemtuzumab ozogamicin; Haplo = haploidentical; HSCT = hematopoietic stem cell transplantation; LMWH = low molecular weight heparin; M = male; MAC = myeloablative conditioning; MMF = micophenolate mofetil; MSD = matched sibling donor; MTX = methotrexate; PO = per os; RIC = reduced intensity conditioning; sAML = secondary AML; SOS = sinusoidal-obstruction syndrome; TCD = T-cell depletion; UCB = umbilical cord blood; UD = unrelated donor; UDAC = ursodeoxycholic acid; VOD = veno-occlusive disease.
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The CI of day-100 acute GVHD was 31 ± 7%. Twenty-three patients experienced grade II, while 22 patients had grades III-IV acute GVHD. For chronic GVHD, the CI at 5 years was 25 ± 7%.
The CI of relapse at 5 years was 42 ± 8% (Figure 2 ), being significantly higher in patients undergoing HSCT with active disease (P = 0.03) in univariate analysis.
The CI of NRM at 5 years was 21 ± 7% ( Figure 2 ). Ninety patients died: 56 of disease recurrence and 34 of transplant-related toxicity. The latter consisted of 15 GVHD-related deaths, 8 infectious causes, 3 SOS, 3 unspecified causes, 2 interstitial pneumonia, 1 cardiac toxicity, 1 hemorrhage and 1 secondary malignancy.
In the univariate analysis, NRM was higher in male patients (P = 0.03) and in those presenting a Karnofsky performance status at HSCT o 90% (P = 0.01).
In the multivariate analysis (Table 4) , active disease at the time of HSCT was independently associated with RI (hazard ratio (HR) 2.33; 95% confidence interval (CI) 1.16-4.71, P = 0.02), and age 450 years was found to be related to a worse NRM (HR 2.83; 95% CI 1.05-7.63, P = 0.03).
OS and LFS With a median follow-up of 64 months, the probability of OS and LFS at 5 years were 40 ± 8% and 37 ± 8%, respectively (Figure 3) .
In the univariate analysis, active disease status (P o 0.001 for both LFS and OS) and experience of hepatic toxicity during GO treatment were associated with poorer OS (P = 0.03) and LFS (P = 0.04). Moreover, a lower LFS was observed in males (P = 0.04).
In multivariate analysis (Table 4) , active disease status was confirmed to be related to a worse LFS (P = 0.02) and OS (P = 0.02), while hepatic toxicity during GO treatment was confirmed to be associated with a worse OS (P = 0.02) but not to a worse LFS (P = 0.06). In addition, neither OS nor SOS incidences were significantly different for patients with an interval ⩽ 3.5 months between GO administration and HSCT as compared with the others (P = 0.16) (Figure 4) . Of note, a worse OS was found in patients undergoing HSCT within ⩽ 1 month from last GO dose (P = 0.032), with a trend to an increased risk of SOS (P = 0.06).
DISCUSSION
SOS is a potentially life-threatening complication occurring after HSCT. Its diagnosis is based on clinical criteria, including weight gain, ascites, tender hepatomegaly and jaundice. The condition usually develops by 30 days after HSCT, although it can occur later. Historically, its reported incidence ranges from approximately 0% to 60%, and this variation is clearly not only related to the intensity and definition of the conditioning regimen, the type of transplant and the presence of known risk factors but also to the clinical criteria used for diagnosis. 1 Finally, this variability may also be related to differences in the AML populations studied in the various reports and to a lack of precision in differentiating SOS from other forms of liver toxicity.
Neither Baltimore nor Seattle clinical criteria take into account the possibility of a late-onset SOS. 20 As we believe that the physician's evaluation is the best tool to identify SOS, we analyzed all cases judged as SOS by the investigators, including those with late onset, occurring at 421 days after HSCT. Each case was classified by the degree of certainty according to established clinical criteria and/or onset temporal sequence, thus distinguishing three types of SOS as definite, possible and confirmed. Abbreviations: BM = bone marrow; GO = gemtuzumab ozogamicin; HLA-id = HLA-identical; HSCT = hematopoietic stem cell transplantation; LFS = leukemia-free survival; MAC = myeloablative conditioning; NRM = non-relapse mortality; OS = overall survival; RIC = reduced-intensity conditioning; UD = unrelated donor.
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In our series, the incidence of SOS after GO treatment before HSCT accounted for 3% of the cases. However, it is not comparable to previous reports of patients developing SOS after GO because we considered a particular population of patients receiving GO, that is, those who were good candidates for HSCT.
We found a CI of SOS of 8% after HSCT at day 150, which is comparable to previously published data in patients undergoing HSCT without prior GO treatment. 1 For instance, a single-center series of 845 patients undergoing HSCT 21 reported a mean incidence of SOS of 9% using the Baltimore criteria and 14% with the Seattle criteria that is lower than that published in early reports. When the CI of SOS was Abbreviations: CI = confidence interval; HR = hazard ratio; HSCT = hematopoietic stem cell transplantation; LFS = leukemia-free survival; MAC = myeloablative conditioning; NRM = non-relapse mortality; OS = overall survival; RI = relapse incidence; RIC = reduced-intensity conditioning; TCD = T-cell depletion. analyzed according to the year of HSCT, its incidence was found to be significantly higher in the 1985-1996 period than in more recent years (1997-2008) (11.5% vs 6.5%; P = 0.001). The lower incidence in recent years is attributed to the use of RIC regimens, the improvement of supportive measures and of results of unrelated HSCT. In a more recent study analyzing a cohort of 257 AML adult patients mostly receiving a busulfan-based MAC regimen, the incidence of SOS was 7.8 ± 2%, with HLA-mismatched donors and patients transplanted in non-remission representing the population at higher risk. 22 Notably, in our series most patients developing SOS had an unrelated donor, but this was not statistically significant.
In the study by Larson et al. 4 evaluating 277 patients aged 460 years after treatment with GO as a single agent at a dose of 9 mg/m 2 , the incidence of SOS increased from 0.9% in non-transplanted patients to 17% in those undergoing HSCT. In younger patients, SOS was reported in 9 out of the 14 (64%) patients receiving GO (as monotherapy or in association with other chemotherapeutic agents, at a dose of 6 or 9 mg/m 2 ) or prior to myeloablative HSCT, compared with 4 out of the 48 (8%) in patients not treated with GO. 5 The authors concluded that the timing of HSCT in relation to GO exposure may be an important factor for those who developed SOS, as 90% of patients who underwent HSCT ⩽ 3.5 months from GO developed SOS vs none in the rest of the group. On the contrary, in our series, an interval between GO administration (at a median lower dose of 3 mg/m 2 ) and HSCT ⩽ 3.5 months did not translate neither into a higher incidence of SOS nor in a worse OS. However, it is worth emphasizing that a worse OS was found in patients undergoing HSCT within ⩽ 1 month from last GO dose, with a trend to an increased risk of SOS, so that when the interval is too short the risk might be increased.
In contrast to the aforementioned studies, in our series 450% of the patients received a RIC regimen, which is associated with a lower rate of toxicity, including SOS. 23 The incidence of SOS in historical cohorts has been described as being nearly 10-15% after MAC vs o 5% following RIC. 21 Our results are in accordance with higher incidence in patients receiving a MAC as compared with patients receiving an RIC regimen (11% vs 5%, P = 0.056).
Similarly, our results agree with those of Chevallier et al. 24 who reported a 7% CI of SOS in a population of 44 patients receiving GO at a higher dose of 9 mg/m 2 in association with chemotherapy prior to HSCT. Most patients (n = 36) in that series received an RIC regimen. Furthermore, in that study, all but one patient received heparin-based SOS prophylaxis.
Prophylaxis of SOS is an important point to consider, as hepatic SOS can cause significant morbidity and mortality, with some unmodifiable risk factors and largely unsuccessful treatment. Therefore, some transplant centers now administer routine prophylactic therapy, especially in high-risk patients, such as patients receiving GO treatment. However, the drugs and regimens used are highly variable, such as the definition of 'high-risk patients', and no widely accepted recommendation or guideline exists on the optimal strategy to prevent SOS.
The first randomized studies reported the efficacy of low-dose heparin in preventing SOS in adults and children, but these data were later not confirmed in larger prospective studies. 25, 26 A metaanalysis focusing on the use of ursodeoxycholic acid also reported its efficacy in preventing SOS, but two other randomized studies showed conflicting results.
Our series confirms the high variability of prophylaxis strategies in different centers, with more than half of the patients undergoing HSCT without receiving SOS prophylaxis despite previous exposure to GO. Interestingly, in patients receiving prophylaxis, this was very heterogeneous with most patients (n = 57) receiving heparin, whereas only 8 and 4 patients receiving ursodeoxycholic acid and defibrotide, respectively. This relatively low exposure to defibrotide might likely reflect the fact that patients included in the current study underwent HSCT before 2013, that is, before defibrotide was formally approved in the treatment of SOS, while there is still no formal approval in prophylaxis, with only two retrospective studies addressing this issue, showing no case of SOS in patients receiving prophylaxis with either defibrotide alone 27 or in combination with heparin, 28 thus highlighting the need of prospective studies.
Somewhat surprising is the fact that 9 out of the 11 patients who developed SOS in our study received SOS prophylaxis, including defibrotide in 2. It is worth emphasizing that the variability of prophylactic strategies is an important limitation of our study, relying on retrospective data extraction. Our results might be interpreted with caution as there are probably important factors that we have not been able to take into account, such as, for example, criteria guiding SOS prophylaxis choice.
Further prospective studies elucidating the role of SOS prophylaxis, especially in this high-risk group of patients receiving GO, are warranted.
In any case, the variability in the reported incidence of SOS in the different studies highlights the need for definition of new diagnostic criteria or of a correct redefinition of SOS taking into account the more recent advances in the transplantation field and including the late-onset forms.
We also report for the first time outcomes of a selected population of patients undergoing HSCT after GO, with an LFS and OS at 5 years of 37% and 40%, respectively, and with a worse OS found in patients experiencing hepatic toxicity during GO treatment.
In conclusion, our results suggest that in a selected population of patients receiving a median low-dose GO of 3 mg/m 2 prior to HSCT, CI of SOS was not significantly higher than that reported in historical cohorts of patients not receiving GO. Moreover, in line with previous reports, higher incidence of SOS after myeloablative conditioning might suggest the use of a less intensive conditioning regimen in those high-risk patients who are in need of transplant despite prior exposure to GO. Moreover, this risk might be lowered in the future with the advent of new prophylactic and therapeutic agents in SOS treatment. The heterogeneity of prophylaxis strategies in our series did not allow to analyze the benefit of one or another strategy, thus highlighting the need for further prospective randomized studies specifically addressing this unmet clinical need.
Our data also highlight the need for a new classification of SOS in order to include late-onset forms, especially owing to the increasing use of reduced intensity and reduced toxicity conditioning regimens in more recent years as compared with the period when Seattle and Baltimore clinical classifications were conceived.
